Principal Financial Group
XENE icon

Principal Financial Group’s Xenon Pharmaceuticals XENE Stock Holding History

Principal Financial Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$453K Buy
7,506
+1,262
+20% +$70.1K ﹤0.01% 2013
2026
Q1 		$363K Buy
6,244
+1,756
+39% +$80.9K ﹤0.01% 2052
2025
Q4 		$201K Sell
4,488
-1,330
-23% -$55.9K ﹤0.01% 2130
2025
Q3 		$234K Buy
+5,818
New +$205K ﹤0.01% 2149

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Principal Financial Group's XENE Position: Q2 2026 in Review

Principal Financial Group increased its Xenon Pharmaceuticals (XENE) stake by 20% in Q2 2026, buying an estimated $70.1K and bringing the position to 7,506 shares worth $453K. The position accounts for ﹤0.01% of the portfolio, ranked #2013.

Principal Financial Group first reported a position in XENE in Q3 2025 and has held it in 4 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Principal Financial Group held 7,506 shares of Xenon Pharmaceuticals worth $453K as of Q2 2026.
  • Principal Financial Group bought 1,262 Xenon Pharmaceuticals shares in Q2 2026, an estimated $70.1K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #2013 holding.
  • Principal Financial Group first reported a position in Xenon Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.